261 related articles for article (PubMed ID: 20980447)
21. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
Williams R; Hudson JM; Lloyd BA; Sureshkumar AR; Lueck G; Milot L; Atri M; Bjarnason GA; Burns PN
Radiology; 2011 Aug; 260(2):581-90. PubMed ID: 21555352
[TBL] [Abstract][Full Text] [Related]
22. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Fournier LS; Oudard S; Thiam R; Trinquart L; Banu E; Medioni J; Balvay D; Chatellier G; Frija G; Cuenod CA
Radiology; 2010 Aug; 256(2):511-8. PubMed ID: 20551183
[TBL] [Abstract][Full Text] [Related]
23. Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment.
Zhou JH; Zheng W; Cao LH; Liu M; Luo RZ; Han F; Wu PH; Li AH
Eur J Radiol; 2012 Jun; 81(6):1360-5. PubMed ID: 21345633
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
25. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy.
Ng CS; Charnsangavej C; Wei W; Yao JC
AJR Am J Roentgenol; 2011 Mar; 196(3):569-76. PubMed ID: 21343498
[TBL] [Abstract][Full Text] [Related]
26. [Usefulness of enhanced ultrasonography after administration of intravenous contrast agent in the evaluation of therapeutic effect in treatment of hepatocellular carcinoma, and efficacy of percutaneous ethanol injection therapy (PEIT) for residual tumor].
Nishiharu T; Maeda N; Hara M; Yamashita Y
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Dec; 61(14):790-5. PubMed ID: 11828757
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of Atypical Hepatocellular Carcinoma from Focal Nodular Hyperplasia: Diagnostic Performance of Contrast-enhanced US and Microflow Imaging.
Li W; Wang W; Liu GJ; Chen LD; Wang Z; Huang Y; Liu JY; Xie XY; Lu MD
Radiology; 2015 Jun; 275(3):870-9. PubMed ID: 25584708
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
29. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.
Bargellini I; Vignali C; Cioni R; Petruzzi P; Cicorelli A; Campani D; De Simone P; Filipponi F; Bartolozzi C
Radiology; 2010 Apr; 255(1):289-300. PubMed ID: 20308465
[TBL] [Abstract][Full Text] [Related]
31. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience.
Sahani DV; Holalkere NS; Mueller PR; Zhu AX
Radiology; 2007 Jun; 243(3):736-43. PubMed ID: 17517931
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Sun W; Sohal D; Haller DG; Mykulowycz K; Rosen M; Soulen MC; Caparro M; Teitelbaum UR; Giantonio B; O'Dwyer PJ; Shaked A; Reddy R; Olthoff K
Cancer; 2011 Jul; 117(14):3187-92. PubMed ID: 21264839
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
[TBL] [Abstract][Full Text] [Related]
34. Contrast-enhanced gray-scale ultrasound for quantitative evaluation of tumor response to chemotherapy: preliminary results with a mouse hepatoma model.
Zhou JH; Cao LH; Zheng W; Liu M; Han F; Li AH
AJR Am J Roentgenol; 2011 Jan; 196(1):W13-7. PubMed ID: 21178025
[TBL] [Abstract][Full Text] [Related]
35. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
Thomas MB; Morris JS; Chadha R; Iwasaki M; Kaur H; Lin E; Kaseb A; Glover K; Davila M; Abbruzzese J
J Clin Oncol; 2009 Feb; 27(6):843-50. PubMed ID: 19139433
[TBL] [Abstract][Full Text] [Related]
37. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT.
Ding H; Kudo M; Onda H; Suetomi Y; Minami Y; Chung H; Kawasaki T; Maekawa K
Radiology; 2001 Dec; 221(3):721-30. PubMed ID: 11719668
[TBL] [Abstract][Full Text] [Related]
39. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions.
Ippolito D; Querques G; Okolicsanyi S; Talei Franzesi C; Pecorelli A; Lombardi S; Orsini E; Strazzabosco M; Sironi S
Eur J Radiol; 2018 Sep; 106():62-68. PubMed ID: 30150052
[TBL] [Abstract][Full Text] [Related]
40. Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound.
Lo GM; Al Zahrani H; Jang HJ; Menezes R; Hudson J; Burns P; McNamara MG; Kandel S; Khalili K; Knox J; Rogalla P; Kim TK
Ultrasound Med Biol; 2016 Jun; 42(6):1303-11. PubMed ID: 27033332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
